Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion
The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones
We haven't written up this one. Quartz has the full story — the link below goes straight to it.